AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03216265 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: No treatment.
Study NCT02002078 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: methylprednisolon
Study NCT01949064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Grindcare
Study NCT01949064 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Michigan-type occlusal splint
Study NCT03763487 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: venous blood sampling
Description: Venous blood samples to determine memory B lymphocytes.
Study NCT03763487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spleen volumetry
Description: Ultrasound examination of spleen to scaled the size.
Study NCT00000451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sertraline
Description: 16 week outpatient study
Study NCT00000451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone
Description: 16 week outpatient study
Study NCT02874794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696 (sacubitril/valsartan)
Description: 24/26mg, 49/51mg and 97/103mg oral, tablets.
Study NCT02874794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: 2.5mg, 5mg, and 10mg, oral, tablets
Study NCT02874794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo of Enalapril
Description: matching placebo (2.5mg, 5mg and 10mg) oral, tablets
Study NCT01385228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Dose Level Xb - daily administration of pazopanib on days 3 through 19 starting at 400mg with a maximum dose of 1000mg.
Study NCT01385228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5mg Prednisone given twice daily days 1-21.
Study NCT01385228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Study NCT02911207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patients choose one creative activity and one physical activity
Description: taking part in 2 activities (a creative one and a physical one)
Study NCT02911207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patients choose one creative activity and one physical activity
Description: taking part in 2 activities (a creative one and a physical one)
Study NCT03335917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia
Description: Participants will be exposed to hypoxia by reducing barometric pressure or by reducing oxygen concentration
Study NCT03335917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Graded cycling exercise to volitional fatigue
Study NCT03335917 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: Graded cycling exercise to volitional fatigue
Study NCT02610959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
Study NCT02610959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
Study NCT00367770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tracleer®
Description: Patients will receive up to 125 mg b.i.d. of Tracleer.
Study NCT03843710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gold Nanocrystals
Description: CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with a concentration of up to 0.5 mg/mL of gold. The formulation is buffered by sodium bicarbonate present at a concentration of 0.546 mg/mL. There are no other excipients. The drug product is formulated to be taken orally and will be provided in single dose HDPE containers. The study doses vary by the concentration of gold nanocrystals per milliliter in a volume of 60 mL.
Study NCT00761150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-712
Description: ABT-712 extended-release tablet
Study NCT00761150 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT01381146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of Crime Modules
Description: 5 session/1 week modules of a restorative justice inspired victim impact group intervention
Study NCT01381146 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TAU
Description: have access to other jail programs and services
Study NCT01857310 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5 mg folic acid and 30 mg elemental zinc
Study NCT01857310 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Study NCT02392845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Docetaxel (DTX) and Epirubicin (EPI)
Description: Six cycles of densified DTX+EPI chemotherapy (2 weeks per cycle) for each patient
Study NCT02207660 — intervention group
Intervention type: DRUG
Intervention: Cisplatin,P-HDFL
Description: The P-HDFL regimen was given as follows: In each 21-day cycle, patients received 24-hour infusions of cisplatin at 45 or 50 mg/m2 and 5-FU 2,600mg/m2 plus leucovorin 300 mg/m2 intravenous 24-hour infusion on Day 1. Normal saline hydration (≧1000 mL), dexamethasone, and antiemetics (ondansetron or granisetron) were given prophylactically before each dose of cisplatin.
Study NCT05039827 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with movement
Description: Heating fermentation was done for 10 minutes as baseline treatment. MWM with wrist extension was given for alternative days in a week as per 3 sessions per week for 4 weeks.
Study NCT05039827 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Soft Tissue Mobilization
Description: Heating fermentation was done for 10 minutes as baseline treatment. Parallel and longitudinal massage was given for alternative days in a week as per 3 sessions per week for 4 weeks
Study NCT01216267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: lansoprazole 30 mg HS x 7 days
Study NCT01216267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole
Description: lanzoprazole 30 mg HS for 7 days
Study NCT04700033 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Somatic IVR (sIVR)
Description: This intervention will consist of an IVR protocol that is focused on somatic interaction that encourages disassociation between pain and visualization and movement of the affected limbs. Subjects in this group will be exposed to an IVR environment that cycles them through a series of stretching and mobility exercises for the affected limbs bilaterally.
Study NCT04700033 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distractive IVR (dIVR)
Description: This intervention will consist of an IVR that is focused on distracting the subject from the pain. Subjects in this group will be exposed to a variety of engaging landscape IVR environments, without the ability to visualize their own body.
Study NCT04700033 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Control IVR (cIVR)
Description: This intervention will consist of an IVR exposure to a black screen for 20 minutes. No light, images or scenery will be present in the IVR and it will serve as a control condition for the trial.
Study NCT01751802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: Antagonist of the dopamine D1 receptor
Study NCT01751802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Ecopipam
Study NCT01376531 — intervention group
Intervention type: PROCEDURE
Intervention: continuous veno-venous hemodialysis
Description: continuous veno-venous hemodialysis
Study NCT02874794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of LCZ696
Description: matching placebo (24/26mg, 49/51mg and 97/103mg) oral, tablets
Study NCT03679481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Description: Following induction of anesthesia and prior to surgical incision, patients will receive 1 gram of intravenous TXA mixed in 100cc of normal saline.
Study NCT04568343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Description: We use two capsule endoscopy for evaluation their diagnostic yield. Patient will recieve different capsule endoscopy:The Endocapsule (EC-10) and CapsoCam Plus (Capsovision) capsule
Study NCT00538265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months
Study NCT03679481 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Following induction of anesthesia and prior to surgical incision, patients will receive 100cc of normal saline.
Study NCT02615106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: 7.5 mg/m2/day, day 1-14
Study NCT02615106 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
Description: 21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
Study NCT03249896 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Habits-GDM mobile app
Description: The intervention is a self-administered mobile app designed for GDM. It targets behavioural change by providing personalised GDM management program which consists of three main elements: lessons, tracking and coaching/feedback. Lessons contains 12 interactive modules which provide patient education on GDM. Each lesson will take approximately 10-20 minutes. Information on SMBG (linked to the Aina or Aina Mini device), weight (linked to the Bluetooth weighing scale), physical activity (physical activity tracking function in the app), and food (equipped with common local food using the Singapore food database) can be tracked and displayed visually. An interactive messaging platform is used for coaching. Generic and customised automated messages are sent from a virtual lifestyle coach to encourage and motivate patients towards healthy behaviour beneficial for GDM.
Study NCT01556945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP1/AS02
Description: The vaccine antigen FMP1 consists of a recombinant histidine-tagged (His6) fusion protein expressed in E. coli. The lyophilized pellet contained per vaccine vial 62.5 μg merozoite surface protein-142 (MSP-142) with 3.1% lactose as cryoprotectant in each 3 ml monodose vial. The pellet was reconstituted with AS02.
Study NCT00538265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus, ATG
Description: immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage.~In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids.~In this study arm, tacrolimus will be administered as in arm (A)
Study NCT01556945 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02
Description: The vaccine antigen RTS,S, is a recombinant subunit vaccine produced in, and purified from yeast cells. The final lyophilized pellet contained 62.5 μg RTS,S with 3.15% lactose as cryoprotectant per 3 ml monodose vial. The pellet was reconstituted in AS02 and each 0.5 ml dose contained 50 μg RTS,S.
Study NCT00538265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG+mycophénolate mofétil+tacrolimus
Description: immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3.~In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months.
Study NCT04300374 — intervention group
Intervention type: OTHER
Intervention: The Paediatric Anaesthesia Emergence Delirium scale assesment which was recorded postoperatively
Description: routine remifentanil infusion during general anesthesia
Study NCT01556945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AS02 adjuvant alone
Description: AS02 adjuvant contains 50 μg monophosphoryl lipid A (MPL) and 50 μg Quillaja saponaria 21 (QS-21), 250 μl of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 ml.
Study NCT01556945 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Malaria challenge
Description: Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
Study NCT02580006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPORON
Description: single dose administration subcutaneously
Study NCT01556945 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Malaria challenge
Description: Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
Study NCT02580006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPREX
Description: single dose administration subcutaneously
Study NCT02772497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziv aflibercept
Description: Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks
Study NCT02665442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Stylet - EsoSure
Description: The Esophageal Stylet is a thin rigid tube, which will be inserted inside a commonly used nasogastric tube placed inside the esophagus during the ablation. We will use this stylet to move the esophagus away from the site of the ablation about 1-2 centimeters.
Study NCT04011436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthening program
Description: Both protocols lasted eight (8) weeks, the anatomical conditioning phase was carried out in two weeks of intervention, followed by 4 weeks of strengthening or strength increase and two additional weeks as a final or maintenance phase, at the end of which performed the final evaluations to identify if there were differences in the groups after the physiotherapeutic intervention.~Group A: 28 exercises Group B: 24 exercises
Study NCT04011436 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Strengthening program
Description: Both protocols lasted eight (8) weeks, the anatomical conditioning phase was carried out in two weeks of intervention, followed by 4 weeks of strengthening or strength increase and two additional weeks as a final or maintenance phase, at the end of which performed the final evaluations to identify if there were differences in the groups after the physiotherapeutic intervention.~Group A: 28 exercises Group B: 24 exercises
Study NCT00698516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)
Description: 2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.
Study NCT02272010 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Diet
Description: Altered n-6 (linoleic acid) and n-3 (eicosapentaenic acid (EPA) + docosahexaenoic acid (DHA)) diet.
Study NCT02272010 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Diet
Description: Diet standardized to the usual American distribution of n-6 (7%) and n-3 EPA+DHA (150 mg per day).
Study NCT00513019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal (lamotrigine)
Description: once daily from beginning to end of study. Dosage varies.
Study NCT00513019 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily
Study NCT00807222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisdexamfetamine dimesylate
Description: Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.
Study NCT00807222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lisdexamfetamine dimesylate
Description: Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.
Study NCT00677456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: R-Y reconstruction after total gastrectomy
Description: Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
Study NCT00677456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: P-Y reconstruction after total gastrectomy
Description: Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the P-Y.
Study NCT01835431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.
Study NCT01466140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Writing down request for help
Description: Patients in the intervention group could write down their request for help on a request card (with a maximum of 2 questions).
Study NCT00926588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stepped care
Description: Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are new tools developed for this study.
Study NCT04218123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Description: Daily oral intake 37.5 mg
Study NCT04218123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Daily oral intake
Study NCT00470184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Oral
Study NCT00470184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: IV
Study NCT00470184 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative Study
Study NCT00470184 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative Study
Study NCT00470184 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: reverse transcriptase-polymerase chain reaction
Description: Correlative Study
Study NCT00470184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy
Description: Metastatic growth control
Study NCT00470184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Examination of tissue type
Study NCT00470184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Tissue removal
Study NCT00470184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Description: Tumor shrinkage
Study NCT00470184 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Correlative Study
Study NCT00470184 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergoing radiation therapy
Study NCT00677456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pouch reconstruction after total gastrectomy
Description: Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border, the distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.